-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Fosclevudine-alafenamide
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1951476-79-1.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 1951476-79-1 |
| Description | Fosclevudine alafenamide (Compound EIDD-02173) is an antiviral agent with an EC50 of 1.71 μM against HBV. |
Product Information
| Synonyms | Fosclevudine alafenamide|SCHEMBL19825437|HY-147269|CS-0542479 |
| Molecular Weight | 529.45 |
| Molecular Formula | C22H29FN3O9P |
| Canonical SMILES | CC1=CN(C(=O)NC1=O)C2C(C(C(O2)COP(=O)(NC(C)C(=O)OC(C)C)OC3=CC=CC=C3)O)F |
| Purity | ≥98% (HPLC) |
| Solubility | 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 911 |
| Exact Mass | 529.16254467 |
| In Vitro | Fosclevudine alafenamide (Compound EIDD-02173) shows cytotoxicity against CEM, A204, IEC-6 and H9c cells. |
| Target | HBV |
| XLogP3-AA | 1.2 |
